An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

Conditions

• Urothelial Carcinoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Atezolizumab [TECENTRIQ] — DRUG
  Atezolizumab 1200 mg will be administered by IV infusion q3w. Initial IV infusion will be given over 60 minutes and subsequent infusions will be given over 30 minutes.

Study Details

This is an open-label, multicenter, single-arm, expanded access program (EAP) designed to provide atezolizumab access to participants with locally advanced or metastatic urothelial carcinoma that has progressed on, or is intolerant to, a platinum-containing chemotherapy regimen.

Key Dates

First listed

Oct 28, 2015

Start date

Nov 30, 2015

Status verified

Nov 2016

Primary completion

Aug 31, 2016

Completion

Aug 31, 2016

Locations (40)

Find similar trials in Scottsdale, AZ

Related Studies

• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  Recruiting · Massive Bio, Inc. · Birmingham, Alabama
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
  PHASE1/PHASE2 · Recruiting · Inhibrx Biosciences, Inc · Duarte, California
• A Multicenter Cancer Biospecimen Collection Study
  Recruiting · Cofactor Genomics, Inc. · San Francisco, California
• An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
  Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas